about
Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis.Influence of neoadjuvant chemotherapy on resection of primary colorectal liver metastases: A propensity score analysis.Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges.Neither Isolated Hepatic Arterial Clamping nor Hepatic Arterial Ligation Induce Ischemic Type Biliary Lesions in Rats.Influence of age on resection of colorectal liver metastases.Pharmacological HIF-inhibition attenuates postoperative adhesion formationIsoflurane does not protect from brain death-associated aggravation of cold hepatic ischemia-reperfusion injury.Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?Prolyl Hydroxylase Inhibition Enhances Liver Regeneration Without Induction of Tumor Growth.Preconditioning by cilostazol protects against cold hepatic ischemia-reperfusion injury.Loss Of Prolyl-Hydroxylase 1 Protects Against Biliary Fibrosis Via Attenuated Activation Of Hepatic Stellate CellsPharmacologic inhibition of hypoxia inducible factor (HIF)-hydroxylases ameliorates allergic contact dermatitisThe phosphodiesterase 3 inhibitor cilostazol does not stimulate growth of colorectal liver metastases after major hepatectomyMechanisms and Consequences of Oxygen and Carbon Dioxide Sensing in MammalsPrognostic relevance of programmed death-ligand 1 expression and microsatellite status in small bowel adenocarcinomaProlyl Hydroxylase Inhibition Mitigates PouchitisPrognostic indicators lose their value with repeated resection of colorectal liver metastasesProtein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?High hepatic expression of PDK4 improves survival upon multimodal treatment of colorectal liver metastasesHypoxia-adaptive pathways: A pharmacological target in fibrotic disease?Mucosal inflammation downregulates PHD1 expression promoting a barrier-protective HIF-1α response in ulcerative colitis patients
P50
Q38663129-78842793-E066-492F-80E8-FFA0E3A23391Q38836982-EA265520-D71D-4CE5-B52F-F387E8CFF12CQ38989150-91B3EF90-0EC4-4385-A737-0399E5D7A7C7Q39264774-1A4893EC-7B4D-4DA6-B57B-1E80442DA663Q41568967-0493FCA0-F2A0-405D-BB1A-5E41017A9731Q42377201-A509FF13-B729-46F0-A984-AC6FA88AFA31Q47761138-A8FD3905-7D3B-4B12-93DD-1A1078A2F1B2Q48163558-3919D96E-39BF-43EE-BEC8-D4BD54DB5D36Q50680919-DEF40FEF-9873-4B81-9B86-7C7F8A2B16E2Q53565933-CC6B1E9D-ED9D-42EA-9C1D-8EEA30823FA9Q57107871-BE685086-0B93-4940-9AE8-475AB5D4BCB4Q58609162-3C4DB428-5CF6-4A83-A2CA-2DAF5B5B573EQ87425591-A2AE4B83-8ABE-4796-8C70-C18B5F3B9040Q90190045-72008D1C-FC38-4B96-94F8-621C351E05BAQ90454640-01634F4E-4A58-42FE-BD58-BE104B967C4AQ90746724-73445FA3-BE27-49F2-9C13-188DC250CAA6Q90986279-19C53B0F-BB18-4C74-9A2E-6A8878F98F9EQ91612348-5F47F51E-C582-44E7-B8F3-6326CB1804C5Q91945266-52980356-FDFA-4FBE-9BA9-CB63092986E7Q92382195-30A9DE7D-D1AC-4E45-8AFE-42A00F7746C7Q92684905-9D293383-0F3D-4C64-94A0-3D4ACC3600CD
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Moritz J Strowitzki
@en
Moritz J Strowitzki
@nl
type
label
Moritz J Strowitzki
@en
Moritz J Strowitzki
@nl
prefLabel
Moritz J Strowitzki
@en
Moritz J Strowitzki
@nl
P31
P496
0000-0001-6967-9283